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Inflammatory periodontal diseases are a leading cause of
tooth loss and are linked to multiple systemic conditions,
such as cardiovascular disease and stroke. Reconstruction of
the support and function of affected tooth-supporting tissues
represents an important therapeutic endpoint for periodontal
regenerative medicine. An improved understanding of peri-
odontal biology coupled with current advances in scaffolding
matrices has introduced novel treatments that use cell and
gene therapy to enhance periodontal tissue reconstruction
and its biomechanical integration. Cell and gene delivery tech-
nologies have the potential to overcome limitations associated
with existing periodontal therapies, and may provide a new
direction in sustainable inflammation control and more predict-
able tissue regeneration of supporting alveolar bone, periodon-
tal ligament, and cementum. This review provides clinicians
with the current status of these early-stage and emerging
cell- and gene-based therapeutics in periodontal regenerative
medicine, and introduces their future application in clinical
periodontal treatment. The paper concludes with prospects
on the application of cell and gene tissue engineering tech-
nologies for reconstructive periodontology. J Periodontol
2011;82:1223-1237.
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T
issue engineering and regenerative
medicine are part of an emerging
multidisciplinary and interdisci-
plinary field that applies the principles
of engineering and the life sciences
toward the development of biologic sub-
stitutes; they have the potential to revo-
lutionize the way health and quality of life
are improved for millions of people
worldwide by restoring, maintaining, or
enhancing tissue and organ function.1
Applied to periodontal biology, tissue
engineering has the potential to improve
the regeneration of lost tooth-supporting
structures in a more predictable manner
than conventional periodontal treatments
(Fig. 1). Periodontal engineering uses
advanced engineering and life science
technologies to restore the structure and
function of alveolar bone, periodontal
ligament (PDL), cementum, and gingival
tissue, recreating the proper periodontal
interface complex characterized by
multitissue integration and proper tissue–
cell orientation.
A successful outcome of periodontal
tissue engineering requires the following
essential factors: appropriate cells, sig-
nals, scaffolds, blood supply, mechanical
loading, and pathogen control. Cells pro-
vide the machinery for new tissue growth
and differentiation, whereas growth fac-
tors and other molecules modulate the
cellular activity and provide stimuli
for cells to differentiate and support
tissue neogenesis. A three-dimensional
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template structure is provided by scaffolds to sup-
port and facilitate these processes that are critical
for tissue regeneration.2 New vascular networks
promoted by angiogenic signals provide the nutri-
tional base for tissue growth and homeostasis,
whereas appropriate mechanical loading is essen-
tial for the development of highly organized, func-
tional PDL fibers. Finally, because of the microbial
load at the periodontal lesion, strategies to control
infection and host response are required to optimize
periodontal regeneration.
This paper reviews the concepts and available
information in tissue engineering concerning early-
stage cell and gene delivery for periodontal therapy.
The discussion focuses primarily on three important
aspects: 1) cell-based therapy, 2) gene therapy,
Figure 1.
Cell- and gene-based technologies using scaffolding matrices for periodontal tissue engineering. A) Extraoral and intraoral stem cells represent a viable
and accessible alternative source to harvest and expand multipotent colonies. Adequate cell density could be reached in vitro under a controlled
environment and made readily available for reimplantation into a periodontal defect site. B) The available direct and cell-based delivery of a
therapeutic gene has been shown to increase the regenerative potential and enhance the availability of important factors. The gene of interest is either
injected directly into the periodontal defect via a retrovirus or alternatively could be incorporated into an embryonic stem cell (ES) or adult stem cell that
is subsequently expanded and delivered into the area of interest. C) Prefabricated and image-based scaffolds are becoming an essential component in
regenerative medicine. A defined supporting structure allows the localization and guidance of the appropriate cells and proteins and the establishment
of a mechanically competent environment. Currently, scaffolds for periodontal regeneration are available in particulated, solid, and injectable forms.
New developing technology has allowed the customization of scaffolds that fit into the periodontal defect and include an external and internal
architecture that enhances tissue orientation and regeneration. This figure highlights the potential of integrating the available tissue engineering strategies
to enhance the outcome of periodontal regenerative therapy.
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and 3) scaffold fabrication technologies for delivering
cells and genes to periodontal osseous defects.
CELLS FOR PERIODONTAL REGENERATION
In general, cell therapy involves the treatment of
disease or disorder by transferring new cells into a
tissue. Cells are the center of new tissue growth
and differentiation. In cell-based regenerative medi-
cine, cells are delivered to a defect site with the goal
of improving the regeneration process.3 Cell delivery
approaches are used to accelerate periodontal regen-
eration through two primary mechanisms: to use cells
as carriers to deliver growth or cellular signals, and
to provide cells that are able to differentiate to multiple
cell types to promote regeneration. The use of cells
as vehicles to deliver growth factors can stimulate an
endogenous regeneration process.1 This strategy
has been intensively investigated in both soft and hard
periodontal tissue regeneration. Stem cell research
has soared in the past few years and the effects on
healing and regenerative potential have been ex-
tensively studied.
Mesenchymal stem cells (MSCs) are self-renew-
able and can differentiate into a variety of cell types
that form mesenchymal and connective tissues.3,4
Bone marrow stromal cells are the most widely inves-
tigated MSCs because they are easily accessible.
Bone marrow stromal cells were initially isolated
and described nearly 50 years ago based on their abil-
ity to adhere to plastic substrates of cell culture
plates.5 Since then, this simple protocol has been
widely used to isolate MSCs from many tissues, such
as adipose tissue, muscle, liver, pancreas, and carti-
lage.6 MSCs have a tremendous potential in regen-
erative medicine because of their multipotency and
capability to form a variety of tissues, including the
periodontium (Table 1).7-21 Regarding periodontal
tissue engineering, both extraoral and intraoral stem
cells can be harvested and then subjected to enrich-
ment and expansion techniques (Fig. 1). Within this
context, multiple sources of stem cells have been
evaluated for the treatment and regeneration of the
periodontium.22
Extraoral MSCs for Oral and Periodontal
Engineering
There is strong potential for the use of MSC sources
from outside the oral cavity for transplantation to
the oral, periodontal, and craniofacial complex.6,9,23
Kawaguchi et al.7 showed that bone marrow MSC
transplantation promoted periodontal regeneration
in experimental Class III defects in dogs. The treat-
ment promoted up to 20% of cementum and bone
regeneration. Using a cell-labeling technique, it was
shown that these cells differentiate into cementoblasts,
PDL fibroblasts, and alveolar bone osteoblasts in
vivo.8 In a subsequent small clinical trial, autolo-
gous, expanded bone-marrow stromal cells mixed
with atelocollagen were transplanted into periodontal
osseous defects at the time of periodontal surgery,
and positive clinical results were obtained. Further-
more, the use of MSCs and platelet-rich plasma
(PRP) demonstrated a reduction in intrabony defect
depth and resolution of bleeding and tooth mobility.24
Bone marrow stromal cells have also been
shown to promote bone healing and dental implant
Table 1.
Preclinical Applications of Cell Therapies for Periodontal Tissue Engineering
Cell Type Autograft/Allograft Defect Type Reference(s)
Bone marrow stromal cells Auto Class III defects 8,9
Auto Periodontal fenestration 10
Auto Osteotomy 11-13
Adipose stromal cells Auto Periodontal palatal defects 14
Periodontal ligament cells Auto Class II defects 15
Auto Periodontal fenestration 16
Allo/Xeno Periodontal fenestration 17
Periodontal ligament stem cells Allo Ectopic 18
Allo Periodontal fenestration 15,19
Auto Periodontal defects 20
Cementoblasts Allo Ectopic 21
Allo Periodontal fenestration 22
Dental follicle cells Allo Ectopic 21,22
Allo Periodontal fenestration 22
Xeno = xenograft; Allo = allograft; Auto = autograft.
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osseointegration.25 In a series of studies, Yamada
et al.10-12 used PRP as an autologous scaffold with
in vitro expanded bone-marrow stromal cells to in-
crease osteogenesis in dental implant surgery. This
‘‘autogenous injectable bone treatment’’ resulted
in higher marginal bone levels, better bone–im-
plant contact, and increased bone density com-
pared to PRP alone and particulated cancellous
bone and marrow control groups. Recently, it was
shown that cells harvested from the bone marrow
can be driven down MSC pathways via a single-pass
perfusion process to promote bone regeneration in
tooth extraction socket and sinus floor augmentation
procedures.26
Adipose tissue is another extraoral and non-cranio-
facial source of MSCs for oral and periodontal tissue
engineering. Its greatest advantage is ease of access.
Tobita et al.13 demonstrated in rats that, mixed with
PRP, adipose-derived stromal cells could promote
periodontal regeneration.
Oral and Craniofacial MSCs for Periodontal
Engineering
Just as PDL is essential for the osteogenesis and ce-
mentogenesis during development and remodeling,
cells derived from this tissue are supportive for the
healing response to injury.27 Transplantation of PDL
cells has shown the potential to regenerate periodontal
attachment apparatus in vivo.14,28 Akizuki et al.15 de-
velopedaPDL cell sheet using temperature-responsive
cell culture dish technique and hyaluronic acid (HA)
carrier. After the transplantation of PDL cell sheets
in small and large preclinical animal models, signifi-
cant cementum formation and anchoring PDL fibers
were observed together with new alveolar bone for-
mation. Using specific labeling techniques, Lekic
et al.16 showed that transplanted PDL cells integrate
and differentiate into newly formed periodontal
tissues.
Specific cell types derived from the periodontium
have also been examined for their potential and roles
in periodontal regeneration. Cementoblasts have been
shown to induce mineralization in an ex vivo model29
and in vivo in periodontal wounds.21 By contrast, peri-
odontal healing was inhibited when less-differentiated
dental follicle cells were delivered in a similar fash-
ion.21 Similarly, progenitor cells isolated from dental
follicle failed to form dentin, cementum, or bone in
vivo, although they expressed high levels of bone sia-
loprotein, osteocalcin, and alkaline phosphatase.30
Such results are suggestive of selective behaviors of
different cell types in periodontal regeneration. PDL
stem cells (PDLSCs) have recently been isolated and
they express several mesenchymal stem cell markers,
such as STRO-1 and CD44, and exhibit osteogenic,
adipogenic, and chondrogenic characteristics under
defined culture conditions.3,22 Implanted PDLSCs
generate cementum and PDL-like structures similar
to native periodontal apparatus.17 In a porcine peri-
odontal defect model, PDLSCs were shown to regen-
erate new bone, cementum, and PDL, and the height
of the new alveolar bone was significantly greater
than that of a ceramic carrier group.28 Combining
PDLSCs with another stem cell population from the
root apical papilla of human teeth (stem cells from
apical papilla), Sonoyama et al.31 generated a ‘‘bio-
root’’ structure encircled with PDL tissue. Most re-
cently, Gault et al.32 have taken autologous PDLSCs
from extracted teeth, grown them in tissue bioreac-
tors, and delivered them onto titanium implants as
a cell transplantation approach. These implants form
ligamentous attachments anchoring bone-to-implant
surface and are termed ‘‘ligaplants.’’ These ligaplants
demonstrated functional loading for extended periods
of time as shown in a case series of human partici-
pants.33 The use of cell therapy approaches as hybrid
living, implantable biomaterials offers another avenue
for oral tissue-engineering strategies.33
Besides stem cell delivery, other strategies have
been developed based on the concept that trans-
planted cells promote regeneration by secreting
growth factors via autocrine and paracrine pathways.
Allogenic foreskin fibroblasts have been shown to
be safe and are able to promote keratinized gingiva
formation at gingival recession defects.34 A tis-
sue-engineered living cellular construct composed
of viable neonatal keratinocytes and fibroblasts was
reported to achieve comparable clinical outcome
as gingival graft35 with strong potential to promote
tissue neogenesis through the stimulation of angio-
genic signals.36
Supporting the significant potential of cell-based
therapy to form a variety of periodontal tissues, these
investigations support the use of this approach to de-
liver important cues that drive the regenerative process.
GENE THERAPY FOR PERIODONTAL
ENGINEERING
Gene therapy is defined as the treatment of disease or
disorder by transferring genetic materials to intro-
duce, suppress, or manipulate specific genes that di-
rect an individual’s own cells to produce a therapeutic
agent.37 This therapeutic concept has emerged as a
promising strategy for the modulation of the host
response triggered by periodontal microbe and the
regeneration of periodontium during diseases. Gene
therapy has several advantages over traditional treat-
ments, such as those involving compounds and pro-
teins: 1) greater sustainability than that of a single
protein or compound application; whereas the half-
lives of pharmaceutical compounds or recombinant
protein usually range from several hours to several
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days, viral vector genes can be expressed in vivo from
weeks to years; 2) gene delivery reduces technical
challenges associated with ex vivo protein expression
and purification, such as palmitoylation and glycosyl-
ation; 3) transient and controlled delivery of genetic
sequences encoding a combinatorial group of regen-
erative factors could mimic the natural biologic heal-
ing response; and 4) coupled with tissue-engineering
strategies, delivery of different genes in a spatially
controlled and bioavailable fashion offers strong
potential in regenerating tissues in three dimensions
at the tooth-ligament–bone interface.
Applied to periodontal tissue engineering, a thera-
peutic gene can be introduced into a patient by either
direct delivery through cell-based delivery method
with or without a scaffolding matrix or indirectly
through ex vivo approaches (Fig. 1). In general,
the indirect or cell-based delivery approach is
considered safer and a more controlled approach
because the targeted cells are isolated and the ther-
apeutic gene is delivered ex vivo under controlled
conditions.
Gene Delivery Methods
Specific conditions are an important consideration for
gene transfer applications:38 1) the required duration
of protein release (transient versus long-term expres-
sion); 2) target cells (dividing and non-dividing cells,
targeted locale of cells); 3) host immune response
to vectors in viral-based approaches; 4) route of
gene delivery (ex vivo or in vivo); and 5) the anatomic
constraints of the target site. For example, a one- or
two-walled defect may require the use of a supportive
carrier, such as a scaffold. Other, more contained de-
fect sites, such as three- and four-wall defects, may be
conducive to the use of an adenoviral vector em-
bedded in a collagen matrix. A wide variety of viral
and non-viral vectors have been developed for gene
delivery. Examples of viral vectors are retroviruses,
lentiviruses, adenoviruses (Ad), and adeno-associ-
ated viruses (AAVs). Non-viral vectors include plas-
mids, DNA polymer complexes, nanobubbles and
microbubbles, and ultrasound (Table 2).39
Retroviral vectors are single-stranded RNA viruses
that are replicated in a host cell through the enzyme
reverse transcription to produce DNA from its RNA
genome, and the resulting reverse-transcribed viral
DNA is incorporated into the host cell’s DNA strand
by an integrase enzyme. When the genetically altered
host cell divides, its descendants contain the viral
DNA copy. These vectors have significant advantages
for sustained and efficient transgene expression that
is ideal for the treatment of life-threatening heredi-
tary disorders, although most retroviruses can only
infect dividing cells. Because the integrase enzyme
may insert the DNA copy into an arbitrary position
of the target cell DNA, endogenous gene expression
may be disrupted by insertional mutagenesis of a
Table 2.
Viral and Non-Viral Gene Therapy Vectors Used in Tissue Engineering
Vector Type Advantages Disadvantages
Retrovirus Viral Non-immunogenic Infects only dividing cells
Constitutive transgene expression Insertional mutagenesis
Lentivirus Viral Infects dividing and non-dividing
cells
Insertional mutagenesis
Infects wide range of cell types Potential pathogenicity
Low immune response Complex large-scale preparation
Adenovirus Viral Infects dividing and non-dividing
cells
Potential immunogenicity
Does not integrate into target cell
genome
Transient expression
Adeno-associated virus Viral Infects dividing and non-dividing
cells
Difficult to produce at high titers
Low immunogenicity Small transgenes
Non-pathogenic in human
Plasmid Non-viral Non-immunogenic Low transduction efficiency
Non-pathogenic
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proto-oncogene or tumor suppressor, and carcino-
genesis may occur.40
Lentiviruses, such as the human immunodefi-
ciency virus, are a specialized class of the retrovirus
family and are characterized by a long incubation
period. Lentiviral vectors are one of the most efficient
methods in gene delivery, being able to transfect both
dividing and non-dividing cells. These vectors are also
integrated into the host cell genome. Despite the
evidence that the insertion sites of lentivirus are more
restricted than other retroviruses, the carcinogenesis
induced by insertional mutation is still a hurdle for
clinical application. Additionally, their human immu-
nodeficiency virus origin raises many concerns re-
garding the possibility that recombination events will
lead to replication-competent viruses.41
Ad are non-enveloped icosahedral viruses com-
posed of a nucleocapsid and a double-stranded linear
DNA genome.42 In contrast to lentiviruses, adenoviral
vectors are attractive gene delivery vehicles because
of a number of features: 1) Ad have high transduction
efficiency in both dividing and non-dividing cells, 2)
Ad do not induce apparent phenotypic changes in
transduced cells, and 3) Ad fail to integrate into the
host genome and remain episomal. These vectors
may be advantageous in periodontal tissue engi-
neering because the transient expression of growth
factors may prevent the overgrowth of newly formed
tissue. However, in large-size craniofacial defects,
the short-term gene expression may be insufficient
to induce complete tissue regeneration.43 One major
concern regarding Ad gene delivery is the strong host
immune response to viral capsid proteins, and viral
backbone modification for reduction of immuno-
genicity has been investigated.43 Recently, several
studies have provided supporting evidence indicat-
ing that local therapeutic Ad seem safe and efficient
in diabetic foot ulcer treatment and periodontal re-
generation.44,45
AAVs derive from the parvovirus family and are
small viruses with a single-stranded DNA genome.39
AAV has attracted considerable interest from gene
therapy researchers because of its several significant
advantages: 1) AAV is currently not related to any
human disease, 2) AAV presents very low immuno-
genicity, and 3) AAV infects both dividing and non-
dividing cells. It has the ability to integrate its genetic
material into the host cell genome at a specific site
in the human chromosome 19, which makes it more
predictable than retrovirus.46 However, random inte-
gration of AAV DNA into the host genome is low but
detectable. A recent report raised concerns about
the clinical use of AAV vectors when mice developed
hepatocellular carcinoma after neonatal injection of
an AAV vector, which is associated with the insertion
in a 6-kb region of chromosome 12.47 Types of
recombinant AAV have been developed either to
remain extrachromosomal or integrate into non-
specific chromosomal sites.39 One disadvantage of
the AAV is that it is small and it can only carry target
DNA usually <5 kb.43
Non-viral alternatives can also deliver genetic ma-
terial into a host’s cell.42 They include naked plasmid,
cationic lipids, polymers, peptides, and physical
methods (electroporation and ultrasound). A major
disadvantage for non-viral delivery methods is that
non-viral gene carriers consistently exhibit signifi-
cantly reduced transfection efficiency. However, be-
cause of their low immunogenicity, lack of DNA
insert size limitation, and potential for large-scale pro-
duction, non-viral vectors will be given more con-
sideration in the future, especially in the field of
siRNA gene therapy.48 In the past decade, a signifi-
cant amount of research has focused on designing
cationic compounds that can form complexes with
DNA and can avoid both in vitro and in vivo barriers
for gene delivery.49 Because of the anatomic ad-
vantage, some non-invasive physical methods may
have a great opportunity in delivering DNA to the
periodontium. Chen et al.50 reported that a gene
transfer approach using ultrasound and nanobubbles
and microbubbles leads to high gene expression in
gingival tissue.
Target Genes
Platelet-derived growth factor. Initially identified as
a platelet-derived mitogen specific for cells of mesen-
chymal origin, platelet-derived growth factor (PDGF)
is a member of a family of multifunctional polypeptide
growth factors.51 PDGF is considered a critical switch
to initiate tissue repair process.
Initial studies showed that Ad-PDGF can effectively
transduce cells derived from the periodontium, in-
cluding osteoblasts, PDL fibroblasts, gingival fibro-
blasts, and cementoblasts, which led to enhancing
mitogenic effect on these cells.52,53 Further studies
demonstrated that Ad-PDGF treatment prolonged
the PDGF signaling effect.54,55 Using in vivo optical
imaging, sustained and localized gene expression
in periodontal lesions for up to 21 to 35 days after
direct gene targeting has been demonstrated.44,56
Regarding the safety profile of Ad gene therapy,
Chang et al.44 demonstrated that Ad–PDGF-B de-
livered in a collagen matrix exhibits acceptable
safety parameters for possible use in human clini-
cal studies. Ad–PDGF-B was well contained within
the localized osseous defect area without viremia
or distant organ involvement. No significant histo-
pathologic changes were observed. Although mi-
nor alterations in specific hematologic and blood
chemistries were seen, most measures were within
normal limits.44
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It has been shown that Ad–PDGF-B transduction
was able to enhance soft tissue defect fill by induction
of human gingival fibroblast migration and prolif-
eration in an ex vivo model. Jin et al.56 demonstrated
that by using collagen as carrier, direct in vivo gene
transfer of Ad–PDGF-B stimulated tissue regeneration
in large periodontal defects. Ad–PDGF-B treatment
resulted in more cell proliferation, a four-fold increase
in bridging bone, and a six-fold increase in cementum
repair above vector alone, whereas bone fill was sig-
nificantly less in Ad–PDGF-1308 (a loss-of-function
mutant of PDGF) treated defects.56 Similarly, in a
dental implant model, Chang et al.57 reported that
Ad–PDGF-B shows regenerative capabilities for bone
tissue engineering and osseointegration in alveolar
bone defects comparable to rhPDGF-BB protein de-
livery in vivo.
Bone morphogenetic proteins. In dentistry, bone
morphogenetic proteins (BMPs) have been shown
to be potent growth factors stimulating alveolar bone
formation. Jin et al.20 used an ex vivo strategy, where
dermal fibroblast were transduced with BMP7 and
transplanted into large mandibular alveolar bone de-
fects. Ex vivo BMP2 gene delivery using autologous
bone marrow MSC has been evaluated using animal
models for periodontal regeneration. This approach
has been shown to regenerate not only cementum
with Sharpey fiber insertion, but also statistically signif-
icant quantities of bone, reestablishing a more normal
relationship among the componentsof the regenerated
periodontal attachment apparatus.58 Gene delivery
by BMP7 resulted in rapid chondrogenesis, with sub-
sequent osteogenesis, cementogenesis, and predict-
able bridging of periodontal bone defects,20 whereas
BMP signaling knockdown by Ad-Noggin tended to
inhibit bone repair and cementogenesis.20,59 In a di-
rect gene therapy approach, Ad-BMP7 delivery with
a collagen matrix significantly enhanced alveolar
bone defect fill, new bone formation, and bone–im-
plant contact in a dental implant model.60 BMPs have
been recently studied for a variety of other periodontal
gene-delivery applications.58,61
Wingless (WNTs). Wnts are a family of 19 secreted
glycoproteins that are crucial for embryonic develop-
ment and post-developmental physiology through
regulation of cell proliferation, differentiation, and
apoptosis.62 In the last several years, the role of
Wnt signaling in bone development, postnatal main-
tenance of bone mass, and tooth morphogenesis
has been investigated, and several pharmaceutical
targets in Wnt signaling pathway for skeletal diseases
have been identified, such as leucine-responsive
regulatory protien 5 and sclerostin.63 The role of
Wnts in periodontal homeostasis and regeneration
remains largely unknown, although recently two stud-
ies highlighted the promising future of regulating
Wnt signaling pathway. Nemoto et al.64 showed that
canonical Wnt/b-catenin signaling has been shown
to inhibit murine cementoblasts differentiation and
enhance cell proliferation. In the other study, Chang
et al.18 transduced human periodontal mesenchymal
cells with retroviral Wnt-4, a non-canonical Wnt, and
transplanted them into the experimental periodontal
defects. The results demonstrated that Wnt-4 gene de-
livery promotes healing of alveolar bone wounds in vivo.
Transcription factors and regulators. In addition
to growth factors, other genes that are critical tran-
scription factors and regulators of osteogenesis, such
as Runx2, Osterix (Osx), and LIM domain mineraliza-
tion protein (LMP), may hold promise in periodontal
tissue engineering, especially in alveolar bone aug-
mentation. Runx2 is a master transcription activator
of osteoblast differentiation. Ex vivo Runx2 gene de-
livery is able to induce bone marrow stromal cells and
dermal fibroblasts to form mineral tissue in vivo.65-67
Osx is a zinc-finger–containing transcription factor
that works downstream of Runx2 in osteoblast dif-
ferentiation. Osx gene knockout results in impaired
osteoblast differentiation and absence of bone for-
mation. Tu et al.68 reported that overexpression of
Osx in bone marrow MSCs by retroviral vectors stim-
ulates healing of critical-sized defects. Using the same
ex vivo strategy, the same group further showed Osx
gene therapy increases bone density and elevates
bone–implant contact in a titanium implant model.69
LMP-1 is an intracellular protein that is highly up-
regulated at the early stage of osteoblast differen-
tiation. It has been shown that gene delivery of
LMP-1 or a truncated version LMP-3 induces effi-
cient bone formation in vivo in heterotopic and or-
thotopic (spine fusion and bone fracture healing)
sites.70-73 The value of LMPs shows potential in
the modulation of periodontal progenitor cells but
still requires further investigation for periodontal
tissue engineering.74
Gene Delivery for Host Modulation of
Periodontal Disease
Acknowledging that tissue regeneration alone is not
the only answer to predictably securing a long-term
stable treatment for the patient with a history of peri-
odontal disease is very important. Host modulation
therapies are therefore rising as an important as-
pect in the control of periodontal diseases and
tissue reengineering.75 Future approaches for tissue
engineering may benefit from dual delivery of tissue
regenerative molecules with either antimicrobial or
host modulatory factors. Based on the understand-
ing that the host response against pathogenic
bacteria is a major cause of periodontal tissue de-
struction, new strategies have been developed to tar-
get these factors, such as MMPs, cathepsins, and
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other osteoclast-derived mediators of bone resorp-
tion.75 Gene therapy has also been investigated for
the possibility of long-term maintenance of therapeu-
tic proteins. Cirelli et al.76 used AAV to deliver the
tumor necrosis factor receptor-immunoglobulin
Fc (TNFR:Fc) fusion gene to experimental Porphyr-
omonas gingivalis–lipopolysaccharide-mediated
bone loss. Gene therapy resulted in sustained thera-
peutic levels of serum TNFR protein for ‡3 months,
and P. gingivalis–lipopolysaccharide-mediated bone
loss volume and density was inhibited after AAV2/
1-TNFR:Fc administration. Tristetraprolin, a key cy-
tokine-regulating RNA-binding protein, downregu-
lates inflammatory cytokines by transferring mRNA
transcripts to degradation machinery.77 Patil et al.77
showed that tristetraprolin overexpression by an
adenoviral vector significantly reduces the expres-
sion of interleukin-6, TNF-a, and prostaglandin E2
in vitro and protects inflammation-induced bone
loss and inflammatory infiltrate in an experimental
periodontitis model. Most recently, Yu et al.78 dem-
onstrated the potential of mitogen-activated protein
kinase phosphatase 1 to prevent alveolar bone loss
in vivo. These findings suggest the possible applica-
tion of gene delivery strategies in the modulation of
periodontal disease progression.
The potential of transferring genetic materials to
modulate specific genes that direct an individual’s
own cells to produce a therapeutic effect is the idea
behind treating a disease by gene therapy. Dictating
Table 3.
Scaffolding Matrices for Delivery of Cells and Genes for Periodontal Engineering
Scaffold Origin Biomaterial Components Application
Naturally Derived Allografts Calcified freeze-dried bone,
decalcified freeze-dried bone
Non-viral vector (PDGF-BB)89

















Polymers PLLA Oral MSCs (PDL fibroblasts)93
PGA Retroviral vector (BMP7);
periosteal cells94


























PGA = polyglycolic acid; PLLA = polylactic acid; PLGA = poly(lactic-co-glycolic acid); TCP = tricalcium phosphate; TGF = transforming growth factor; FGF =
fibroblast growth factor; IGF = insulin-like growth factor; Ca-P = calcium phosphate; bFGF = basic fibroblast growth factor.
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the local spatial and temporal distribution of the
gene-therapy effect has been enhanced by their in-
corporation into natural and synthetic scaffolds.
SCAFFOLDING MATRICES USED TO DELIVER
CELLS AND GENES FOR PERIODONTAL
REGENERATION
Scaffolding matrices are used in tissue engineering to
provide an environment where space is created and
maintained during a period of time for cellular growth
and tissue in-growth. These matrices serve as three-
dimensional template structures to physically sup-
port and facilitate periodontal tissue regeneration
when combined with cell- or gene-based tissue engi-
neering (Fig. 1). During the past two decades, scaf-
folds have been extensively developed, studied, and
used. Several fundamental requirements for scaffold
design have been proposed.79 In their application to
tissue engineering, they should 1) provide a three-
dimensional architecture that supports a desired
volume, shape, and mechanical strength; 2) consist
of a high porosity and surface-to-volume ratio with
a well-interconnected open pore structure to pro-
mote high seeding density and embrace bioactive
molecules; 3) be biocompatible; and 4) degrade at
a controlled rate and pattern that allows sufficient
support until tissue defects are fully regrown. Scaf-
folds can also be engineered to serve as supportive
carriers that conduct a sustained release of bioactive
factors, thereby inducing stimuli for tissue formation.
Transplantation of cells can be carried via tissue-
engineered scaffolds79,80 that provide adhesion and
anchorage for interacting stem cells to control the
presentation of adhesion sites, thereby improving cell
survival and participation.81,82 By furthering the pat-
tern of tissue structure formed by stem cells, a new
mandible was formed in a patient by using a metal
and polymer scaffold seeded with stem cells and
BMPs.83 Bioactive molecules, such as growth fac-
tors, may also be encapsulated into nanoparticles
and microparticles embedded into the matrices to
aid in their sustained release from scaffolds. Other
approaches include mimicking stem cell niches to
regulate daughter cell proliferation, differentiation,
and dispersion into surrounding tissue or by attract-
ing useful cells to a desired anatomic site.1
Understanding that proper periodontal regenera-
tion is supported by important factors that include
multiple tissue integration and cell–tissue directional-
ity is critical for the optimization and further develop-
ment of emerging scaffold technologies.84,85 Today,
the feasibility to establish a three-dimensional polarity
and a customizable microscaffold and macroscaf-
fold architecture is one step forward to the ability
to create biomimetic scaffold surfaces that are
amenable for gene- and cell-therapy strategies.86
Several scaffold fabrication technologies as applied
to periodontal tissue engineering have developed
during the past 10 years including conventional
prefabricated scaffolds, such as particulated, solid
form, and injectable scaffolds that are adapted
or administered into a periodontal defect, and
novel image-based designs that result in a three-
dimensional printed scaffold that is custom fit to
a defect (Fig. 1).
Prefabricated Scaffolding Matrices
Conventional scaffolds used to regenerate tissue in
vivo are prefabricated, and many techniques have
been described that produce both natural and syn-
thetic polymeric scaffolds. Naturally derived scaffolds
include autografts, allografts, and xenografts. Other
Figure 2.
Hybrid scaffolds for periodontal cell and gene delivery. A through C) Surgically created Class III furcation defect is observed in this figure. The image-
based scaffold aims at generating a three-dimensional polarity and patterning within the defect geometry to guide and establish cell–tissue integration
and directionality.
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naturally derived scaffolds that have been adapted for
tissue regeneration but remain unexplored as carriers
in gene and cell therapy approaches for periodontal
engineering include the coral-derived matrices
and the hydroxyapatite and chitosan carriers.87,88 Al-
loplasts and other polymers are synthetically engi-
neered materials consisting of bioactive molecules
serving a purpose similar to that of natural scaffolds
(Table 3).7,15,16,29,32,44,80,89-97
Synthetic polymers have been studied extensively
as gene therapy delivery systems because they pro-
vide greater freedom for property modification, such
as control of macrostructure and degradation time,
compared to naturally derived scaffolds.98 Further-
more, the release mechanism and exposure duration
of bioactive molecules, such as growth factors, can
be controlled.39 By acting as a localized gene depot,
synthetic polymer scaffolds have the ability to main-
tain the therapeutic level of encoded proteins that
limit unwanted immune response and potential side
effects.99 Such polymers as poly(lactic-co-glycolic
acid) have drawn much attention for its excellent
properties for encapsulation of genes.100 Poly(lactic-
co-glycolic acid) microspheres have been used
previously to deliver antibiotics, as an occlusive
membrane for guided tissue regeneration, as growth
factor carrier for periodontal regeneration, and
for cementum and complex tooth structure engineer-
ing.29,101-105 Microsphere systems have demon-
strated promising results in the past; however, more
novel approaches to microtechnologies today are
focusing on nanosized particles.106 Nanotechnology
has been attracting much attention for therapeutic
agent and gene delivery, and a number of studies
and reviews have delineated its contribution and ca-
pability to meet challenges of current regeneration
therapy.100,106,107 Nanoscaled fibrillar structure of
collagen shows promising effects on cellular biologic
activities, and therefore, the potential of a synthetic
polymer scaffold that mimics the nanofibrous struc-
ture of collagen.108 Furthermore, a recent study has
Figure 3.
The hybrid scaffold concept has proved effective at establishing an
adequate periodontal tissue interface that integrates the newly formed
cementum, bone, and properly oriented PDL fibers. A) The main two
compartments of the scaffold are depicted as PDL region (red) and
bone region (blue). B) A rapid prototyping technique is used to
generate the three-dimensional geometry. C) Wax molds for PDL
and bone architectures are manufactured and fabricated to cast polymeric
materials, poly-glycolide (PGA) for PDL and poly-e-caprolactone (PCL)
for bone of the hybrid scaffold. D) Microcomputed tomography (m-CT)
showed that the designed hybrid scaffold guides multiple tissue
formation with the specific dimension in PDL interface (red dash-lined
box) and bone region (blue dash-lined box). The hematoxylin and eosin
staining was used to analyze mineralized tissue formation and fibrous
connective tissue formation (scale bar = 50 mm original magnification x10).
In PDL interface, fibrous tissue orientation along the PDL topography
(yellow dash-lined border) was found with blood vessel formations (red
triangles) and limited cementum-like layer formation on the tooth
dentin surface (yellow triangles).86
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developed macroporous polymer scaffolds with vary-
ing pore wall architecture to enhance the environment
for induction of cellular activity and provide guidance
for three-dimensional regeneration.109 Therefore,
a delivery scaffold can provide a suitable environment
for targeted cells and tissues and controlling the dy-
namic release of entrapped biologics. Periodontal
therapy based on these systems, however, remains
in its infancy.
The use of HA in the dental field has been demon-
strated to restore periodontal defects and to carry and
deliver growth factors, such as BMPs and fibroblast
growth factor-2.110 Although no clinical or in vivo
studies have used HA for gene and cell therapy strat-
egies for periodontal engineering purposes, a recent
in vitro study has shown an HA and collagen combi-
nation scaffold to be a suitable environment for the
growth of human PDL cells, therefore indicating its
potential for periodontal tissue engineering.111
Inorganic calcium-phosphate–based materials
have also been used as delivery systems. Such
materials as b-tricalcium phosphate are synthetic
scaffolds that can be used to repair osseous defects
around teeth or dental implants by acting as a bone
substitute or as a carrier for growth factor delivery
and cells.90 Gene- and cell-therapy tissue-engineering
methods have used b-tricalcium phosphate as a
carrier for bone reengineering approaches but its
value for periodontal regeneration remains to be
explored.112,113
Hydrogels, formed by the cross-linking or self-
assembly of a variety of natural or synthetic hydro-
philic polymers to produce structures that contain
over 90% water, are obtained from natural materials,
such as collagen chitosan, dextran, alginate, or fi-
brin. They are favorable for tissue engineering be-
cause of their innate ability to interact with and
mediate degradation by cells.106,114-116 Vector re-
lease from hydrogels is dependent on the physical
structure and degradation of the hydrogel and its
interactions with the vector.116
Computer-Based Applications in Scaffold
Design and Fabrication
Computer-based applications in tissue engineering
are some of the more recent developments in scaffold
design and fabrication for cell and gene delivery.117
This type of technology, image-based design, has
been used in recent years to define virtual three-di-
mensional models for surgical planning by using data
from computed tomography and magnetic resonance
imaging. Specifically, in tissue engineering, com-
puted tomography or magnetic resonance imaging
data are used to define the three-dimensional ana-
tomic geometry of a defect that can be used to create
a template for a scaffold on a global anatomic level.
This three-dimensional printed scaffold, because it
is produced from the three-dimensional model, pre-
cisely fills the defect space (Fig. 2). Furthermore,
the architecture of the scaffold can be defined to de-
sign the heterogeneous internal structure in a way
to create region-specific variations in porous micro-
structures and scaffold surface topography, thereby
altering material and biologic properties in specific re-
gions of the scaffold, such as modulus, permeability,
and cell orientation.118 This new generation of scaf-
folds is addressing specific periodontal functional re-
quirements, such as PDL fiber orientation and tissue
integration of cell- and gene-based technologies
(Fig. 3).86
Various novel delivery scaffolding systems are be-
ing extensively studied and fabricated and are demon-
strating capabilities to meet the challenges of current
regeneration therapy. There are several techniques
and technologies that have been developed and ap-
plied to fabrication of scaffold matrices. Only through
further research and development in this area, along
with cell-based and gene therapy, can tissue engi-
neering continue to advance.
FUTURE DIRECTIONS IN PERIODONTAL
REGENERATION
Tissue engineering is making an important impact on
periodontal therapy. The use of cell and gene therapy
to enhance and direct periodontal wound healing into
a more predictable regenerative path is being exploited
in bioengineering efforts that aim at developing a thera-
peutic system to promote periodontal repair. However,
numerous challenges remain. As discussed within the
content of this review, there are a number of developing
systems that have the potential to optimize tissue-heal-
ing biology. A major obstacle that remains today is how
to maximize the use of cells and genes delivered to
a passive or permissive environment where there is
context for the type of cell needed, but in which some
biologic signals are given to encourage normal cell
function. The tissue-engineering field still needs to con-
front other hurdles, such as identifying cell sources and
clinically relevant cell numbers, the integration of new
cells into existing tissue matrices, and the achievement
of functional properties of tissue equivalents using an
expanded repertoire of biomaterials. Major constraints
to the cell- and gene-transfer fields remain in the prac-
tical and regulatory requirements to apply these tech-
nologies to the clinical arena.
CONCLUSIONS
Today, the available cell-based therapy strategies
founded on tissue-engineering approaches have the
most solid background for clinical application in hu-
man periodontal defects. Gene-based therapy is at
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the preclinical level at this point, and as such it may
be several years before it enters the clinical arena.
However, the cell-based, scaffold, and gene-therapy
methods collectively interface and complement each
other to enhance the potential to restore tissue func-
tion and structure in a predictable manner. The success
and the future of periodontal regenerative therapy will
thereby be supported by our understanding and
ability to recognize those clinical situations that
will benefit from one or more of these new emerging
technologies.
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